Continuum of Renin-Independent Aldosteronism in Normotension
- PMID: 28289182
- PMCID: PMC5391287
- DOI: 10.1161/HYPERTENSIONAHA.116.08952
Continuum of Renin-Independent Aldosteronism in Normotension
Abstract
Primary aldosteronism is a severe form of autonomous aldosteronism. Milder forms of autonomous and renin-independent aldosteronism may be common, even in normotension. We characterized aldosterone secretion in 210 normotensives who had suppressed plasma renin activity (<1.0 ng/mL per hour), completed an oral sodium suppression test, received an infusion of angiotensin II, and had measurements of blood pressure and renal plasma flow. Continuous associations between urinary aldosterone excretion rate, renin, and potassium handling were investigated. Severe autonomous aldosterone secretion that was consistent with confirmed primary aldosteronism was defined based on accepted criteria of an aldosterone excretion rate >12 μg/24 hours with urinary sodium excretion >200 mmol/24 hours. Across the population, there were strong and significant associations between higher aldosterone excretion rate and higher urinary potassium excretion, higher angiotensin II-stimulated aldosterone, and lower plasma renin activity, suggesting a continuum of renin-independent aldosteronism and mineralocorticoid receptor activity. Autonomous aldosterone secretion that fulfilled confirmatory criteria for primary aldosteronism was detected in 29 participants (14%). Normotensives with evidence suggestive of confirmed primary aldosteronism had higher 24-hour urinary aldosterone excretion rate (20.2±12.2 versus 6.2±2.9 μg/24 hours; P<0.001) as expected, but also higher angiotensin II-stimulated aldosterone (12.4±8.6 versus 6.6±4.3 ng/dL; P<0.001) and lower 24-hour urinary sodium-to-potassium excretion (2.69±0.65 versus 3.69±1.50 mmol/mmol; P=0.001); however, there were no differences in age, aldosterone-to-renin ratio, blood pressure, or renal plasma flow between the 2 groups. These findings indicate a continuum of renin-independent aldosteronism and mineralocorticoid receptor activity in normotension that ranges from subtle to overtly dysregulated and autonomous. Longitudinal studies are needed to determine whether this spectrum of autonomous aldosterone secretion contributes to hypertension and cardiovascular disease.
Keywords: aldosterone; hypertension; normotensive; potassium; primary aldosteronism; renin.
© 2017 American Heart Association, Inc.
Figures
Comment in
-
Primary Aldosteronism or Not Primary Aldosteronism: Is This Now the Question in Normotension?Hypertension. 2017 May;69(5):780-781. doi: 10.1161/HYPERTENSIONAHA.117.09050. Epub 2017 Mar 13. Hypertension. 2017. PMID: 28289179 No abstract available.
Similar articles
-
The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study.Ann Intern Med. 2017 Nov 7;167(9):630-641. doi: 10.7326/M17-0882. Epub 2017 Oct 10. Ann Intern Med. 2017. PMID: 29052707 Free PMC article.
-
The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study.Ann Intern Med. 2020 Jul 7;173(1):10-20. doi: 10.7326/M20-0065. Epub 2020 May 26. Ann Intern Med. 2020. PMID: 32449886 Free PMC article.
-
Renin Phenotypes Characterize Vascular Disease, Autonomous Aldosteronism, and Mineralocorticoid Receptor Activity.J Clin Endocrinol Metab. 2017 Jun 1;102(6):1835-1843. doi: 10.1210/jc.2016-3867. J Clin Endocrinol Metab. 2017. PMID: 28323995 Free PMC article.
-
Evolution of the Primary Aldosteronism Syndrome: Updating the Approach.J Clin Endocrinol Metab. 2020 Dec 1;105(12):3771-83. doi: 10.1210/clinem/dgaa606. J Clin Endocrinol Metab. 2020. PMID: 32865201 Free PMC article. Review.
-
Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism.Semin Nephrol. 2013 May;33(3):265-76. doi: 10.1016/j.semnephrol.2013.04.007. Semin Nephrol. 2013. PMID: 23953804 Free PMC article. Review.
Cited by
-
Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism.Endocrine. 2024 Mar 6. doi: 10.1007/s12020-024-03751-1. Online ahead of print. Endocrine. 2024. PMID: 38448679 Review.
-
Endocrine Hypertension: The Urgent Need for Greater Global Awareness.touchREV Endocrinol. 2023 Nov;19(2):31-41. doi: 10.17925/EE.2023.19.2.11. Epub 2023 Oct 20. touchREV Endocrinol. 2023. PMID: 38187076 Free PMC article. Review.
-
Efficacy of Oral Furosemide Test for Primary Aldosteronism Diagnosis.J Endocr Soc. 2023 Nov 24;8(1):bvad147. doi: 10.1210/jendso/bvad147. eCollection 2023 Dec 1. J Endocr Soc. 2023. PMID: 38075562 Free PMC article.
-
Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study.Circulation. 2024 Jan 9;149(2):124-134. doi: 10.1161/CIRCULATIONAHA.123.066389. Epub 2023 Nov 30. Circulation. 2024. PMID: 38031887
-
Epidemiology and diagnosis of primary aldosteronism. What have we learned from the SPAIN-ALDO registry?Endocrine. 2024 Mar;83(3):527-536. doi: 10.1007/s12020-023-03573-7. Epub 2023 Oct 26. Endocrine. 2024. PMID: 37884825 Review.
References
-
- Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF., Jr The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism. 2016;101:1889–1916. - PubMed
-
- Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G. Progress in aldosteronism: A review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. European Journal of Endocrinology. 2015;172:R191–203. - PubMed
-
- Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161–165. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
